The application of plasma tartrate-resistant acid phosphatase to assess changes in bone resorption in response to artificial menopause and its treatment with estrogen or norethisterone
Language English Country United States Media print
Document type Journal Article
PubMed
2509014
DOI
10.1007/bf02556018
Knihovny.cz E-resources
- MeSH
- Adult MeSH
- Estrogens therapeutic use MeSH
- Acid Phosphatase blood MeSH
- Drug Resistance physiology MeSH
- Middle Aged MeSH
- Humans MeSH
- Menopause metabolism physiology MeSH
- Norethindrone therapeutic use MeSH
- Ovariectomy MeSH
- Bone Resorption drug therapy metabolism physiopathology MeSH
- Tartrates pharmacology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Estrogens MeSH
- Acid Phosphatase MeSH
- Norethindrone MeSH
- Tartrates MeSH
Plasma tartrate-resistant acid phosphatase (TR ACP), urinary hydroxyproline excretion (UH), serum osteocalcin, and bone alkaline phosphatase isozyme were determined in a prospective study in 31 women who had undergone bilateral ovariectomy (OOX). Nine patients were followed up for 1 year without treatment and for the following 3 years when on mestranol (M) substitution. On the basis of UH, 22 patients were identified as having increased bone resorption (BR) within 3 months of OOX. Subsequently, 11 patients were treated with transdermal estradiol (E2) and 11 patients with norethisterone (norethindrone, NE). In untreated patients, the biochemical indices of BR peaked 3-6 months following OOX and biochemical indices of bone formation (BF) continued to increase from 3 until 12 months. The substitution with both E2 or M resulted in normalization in serum and urinary calcium, serum phosphate, renal threshold phosphate concentration (TmPO4/GRF), and biochemical indices of BR within 4 months of treatment. Biochemical indices of BF normalized within 6 months of treatment. In the M-treated group, these effects continued for 3 years of the follow-up. The hormonal substitution had a protective effect on cortical and lumbar spine bone mass. A significant decrease, but not to normal values, in biochemical indices of BR and a persistent elevation in indices of BF were found in NE-treated patients. Unlike E2, NE does not depress osteoblastic function. There is strong evidence supporting the utility of measurements of TR ACP in plasma in examination of women who had ovariectomies and in assessement of the efficacy of treatment.
See more in PubMed
Obstet Gynecol. 1984 Jun;63(6):759-63 PubMed
N Engl J Med. 1986 Jun 19;314(25):1615-20 PubMed
J Biol Chem. 1985 May 10;260(9):5768-76 PubMed
Lancet. 1987 May 16;1(8542):1105-8 PubMed
Clin Chim Acta. 1985 Oct 15;151(3):273-83 PubMed
Clin Chim Acta. 1967 Jul;17(1):107-10 PubMed
Bone Miner. 1987 Nov;3(2):177-83 PubMed
Clin Chem. 1980 Mar;26(3):420-2 PubMed
J Clin Invest. 1987 Nov;80(5):1261-9 PubMed
Br Med J (Clin Res Ed). 1987 Sep 26;295(6601):757-60 PubMed
J Bone Miner Res. 1989 Feb;4(1):47-55 PubMed
J Biol Chem. 1980 Jun 25;255(12):5864-70 PubMed
Clin Endocrinol (Oxf). 1972 Jan;1(1):57-64 PubMed
Clin Chem. 1987 Apr;33(4):458-62 PubMed
Bone. 1987;8(5):279-84 PubMed
Science. 1988 Jul 1;241(4861):84-6 PubMed
N Engl J Med. 1983 Dec 8;309(23 ):1405-7 PubMed
Calcif Tissue Int. 1989 Feb;44(2):74-9 PubMed
Calcif Tissue Int. 1985 Sep;37(5):526-9 PubMed
Am J Clin Pathol. 1974 Jan;61(1):114-7 PubMed
Clin Sci (Lond). 1985 Sep;69(3):265-71 PubMed
Arch Gynakol. 1964 Feb 4;199:335-9 PubMed
Clin Chim Acta. 1976 May 17;69(1):1-9 PubMed
Lancet. 1975 Aug 16;2(7929):309-10 PubMed
Clin Endocrinol (Oxf). 1986 Nov;25(5):543-7 PubMed
Anal Biochem. 1983 Jul 15;132(2):254-8 PubMed
Enzyme. 1985;33(1):34-40 PubMed
Clin Chim Acta. 1983 Sep 30;133(2):189-200 PubMed
Obstet Gynecol. 1988 Nov;72(5 Suppl):12S-17S PubMed
Ann Intern Med. 1987 Jan;106(1):40-5 PubMed
J Clin Endocrinol Metab. 1987 May;64(5):1079-82 PubMed
Obstet Gynecol. 1985 Dec;66(6):789-92 PubMed
